Phase I/II trial of SGI 1776 in patients with refractory leukaemias.
Phase of Trial: Phase I/II
Latest Information Update: 11 Nov 2010
At a glance
- Drugs SGI 1776 (Primary)
- Indications Leukaemia
- Focus Adverse reactions
- 11 Nov 2010 Due to adverse events, the trial status changed from planning to discontinued, according to a SuperGen media release.
- 04 Dec 2008 New trial record.
- 20 Nov 2008 SuperGen has reported clearance of its Original Investigational New Drug Application in a media release.